King Pharmaceuticals Completes Initial Dosing in Phase I Trial Involving Treatment for Chronic Diabetic Neuropathic Foot Ulcers
Aderis Pharmaceuticals’ partner, King Pharmaceuticals, today announced that King’s Phase I trial has completed the initial dosing of MRE0094, a novel adenosine A2A receptor agonist.
Hopkinton, MA - Jan 13, 2004 - Aderis Pharmaceutical's partner for MRE-0094, King Pharmaceuticals, initiated the Phase I dosing for chronic diabetic neuropathic foot ulcers. This adenosine A2A agonist is designed to utilize a novel approach to treating this condition by concentrating on the inflammation associated with such foot ulcers. Read the complete release from King.
"At Aderis, we are excited about the progress of our product candidates and their potential ability to improve quality of life for millions of people. We are committed to helping patients and investors understand our progress as we achieve corporate and clinical milestones."
-Kenneth L. Rice, Jr.,
Chief Commercial Officer, Aderis Pharmaceuticals
back to top
